Andrew K Godwin

Q: What Schools Are Affiliated With Andrew K Godwin

Andrew K Godwin is affiliated with the following schools: Ohio State University, University of Kansas, University of Brescia, Stanford University, Temple University, Karolinska Institute, University of Ferrara, University of Cambridge, University of Southampton, University of Alabama at Birmingham, Medical University of Vienna, Washington University in St. Louis, University of California, Berkeley

Andrew K Godwin's AcademicInfluence.com Rankings

Andrew K Godwin

Computer Science

#5140

World Rank

#5431

Historical Rank

Computational Linguistics

#646

World Rank

#658

Historical Rank

Machine Learning

#1251

World Rank

#1271

Historical Rank

Artificial Intelligence

#1481

World Rank

#1510

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Andrew K Godwin's Degrees

PhD Computer Science Stanford University
Masters Computer Science University of California, Berkeley
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Andrew K Godwin Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Andrew K Godwin's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Integrated Genomic Analyses of Ovarian Carcinoma (2011) (6411)
The Molecular Taxonomy of Primary Prostate Cancer (2015) (2116)
Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (2007) (1178)
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation (2018) (984)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. (1992) (900)
Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas (1995) (893)
Integrated genomic and molecular characterization of cervical cancer (2017) (762)
AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. (1992) (759)
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. (2007) (707)
A Grb2-associated docking protein in EGF- and insulin-receptor signalling (1996) (685)
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. (1999) (676)
Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. (1995) (669)
Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group. (2009) (585)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. (2012) (544)
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer (2013) (534)
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. (2015) (534)
Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (480)
Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2011) (447)
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth (2004) (424)
Genome-wide association studies identify four ER negative–specific breast cancer risk loci (2013) (411)
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk (2013) (405)
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. (2018) (381)
Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes (2012) (371)
BRCA2 germline mutations in male breast cancer cases and breast cancer families (1996) (363)
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. (2017) (361)
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 (2010) (341)
Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer (2009) (336)
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. (1998) (316)
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families (1996) (313)
Frequent Downregulation of miR-34 Family in Human Ovarian Cancers (2010) (311)
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer (2011) (306)
Focus on epithelial ovarian cancer. (2004) (304)
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27 (2003) (299)
Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. (2003) (295)
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. (2016) (284)
Ovarian Cancer Biomarker Performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Specimens (2011) (283)
Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. (1996) (279)
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. (2007) (276)
Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip (2019) (272)
Development of a multimarker assay for early detection of ovarian cancer. (2010) (262)
Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. (1999) (259)
Phase II Study of Gefitinib in Patients with Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression: A Gynecologic Oncology Group Study (2005) (251)
Repertoire of microRNAs in Epithelial Ovarian Cancer as Determined by Next Generation Sequencing of Small RNA cDNA Libraries (2009) (250)
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2008) (238)
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors (2008) (231)
Lab on a Chip Integrated immunoisolation and protein analysis of circulating exosomes using microfluidic technology †‡ (2014) (227)
Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. (2013) (225)
The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability (1999) (220)
Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. (2011) (212)
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers (2017) (211)
A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas (2011) (208)
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (2018) (206)
Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas (1997) (205)
Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing (2018) (204)
Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management (2009) (204)
Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. (2011) (200)
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. (2010) (196)
Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary (2000) (195)
PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. (2011) (194)
Proteogenomic Characterization of Endometrial Carcinoma (2020) (194)
Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. (2010) (193)
FOXA1 is an essential determinant of ERα expression and mammary ductal morphogenesis (2010) (192)
Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. (1995) (191)
Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. (1992) (190)
Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
Novel glycan biomarkers for the detection of lung cancer. (2011) (185)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. (2012) (182)
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. (2001) (180)
Identification of six new susceptibility loci for invasive epithelial ovarian cancer (2014) (176)
Macrophage-derived extracellular vesicle-packaged WNTs rescue intestinal stem cells and enhance survival after radiation injury (2016) (175)
Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer (2011) (174)
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. (2001) (167)
Molecular genetic evidence that endometriosis is a precursor of ovarian cancer (2006) (165)
Hypomethylation of the Synuclein γ Gene CpG Island Promotes Its Aberrant Expression in Breast Carcinoma and Ovarian Carcinoma (2003) (163)
BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays (2007) (163)
Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumors. (2002) (163)
Identification of two candidate tumor suppressor genes on chromosome 17p13.3. (1996) (158)
ALT-associated PML bodies are present in viable cells and are enriched in cells in the G(2)/M phase of the cell cycle. (2000) (156)
Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (154)
Plasma cell‐free DNA in ovarian cancer (2010) (151)
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. (2014) (145)
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. (1998) (145)
Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing (2014) (144)
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores (2017) (142)
LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer. (2010) (142)
FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells (2012) (139)
Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion (2013) (139)
Relationship between platinum-DNA adduct formation and removal and cisplatin cytotoxicity in cisplatin-sensitive and -resistant human ovarian cancer cells. (1994) (138)
Communication of BRCA1 and BRCA2 results to at‐risk relatives: A cancer risk assessment program's experience (2003) (137)
Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. (2001) (137)
γ-Synuclein Promotes Cancer Cell Survival and Inhibits Stress- and Chemotherapy Drug-induced Apoptosis by Modulating MAPK Pathways* (2002) (137)
Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines. (1993) (135)
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer (2007) (134)
A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. (2011) (133)
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. (1994) (129)
Expression of constitutively activated EGFRvlll in non‐small cell lung cancer (2003) (128)
Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. (2007) (128)
BRCA1 and BRCA2 Mutation Carriers, Oral Contraceptive Use, and Breast Cancer Before Age 50 (2006) (124)
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. (2011) (124)
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2009) (124)
Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170 (2016) (122)
Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. (2003) (122)
Identification of a gene containing zinc-finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. (1997) (122)
The biology of ovarian cancer development (2010) (121)
Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells. (2005) (118)
Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. (2003) (117)
Ovarian cancer biology. (1991) (115)
19p13.1 is a triple-negative-specific breast cancer susceptibility locus. (2012) (115)
Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds. (1996) (114)
Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells (2010) (113)
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (112)
Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling (2005) (112)
A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. (1996) (112)
Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. (1994) (110)
Identification of a zinc-finger gene at 6q25: a chromosomal region implicated in development of many solid tumors (1997) (110)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2019) (110)
Subtypes of familial breast tumours revealed by expression and copy number profiling (2010) (110)
Genetics and ovarian carcinoma. (1998) (109)
Familial cancer associated with a polymorphism in ARLTS1. (2005) (107)
Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome (2011) (106)
Elevated JNK activation contributes to the pathogenesis of human brain tumors (2002) (104)
Erratum : The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075)) (2018) (103)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (103)
A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. (2012) (102)
Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts (2016) (102)
Autonomy of the epithelial phenotype in human ovarian surface epithelium: Changes with neoplastic progression and with a family history of ovarian cancer (1996) (102)
Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. (1995) (101)
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (2011) (101)
WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome (2005) (101)
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. (2012) (98)
Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence. (2011) (98)
Altered expression of the septin gene, SEPT9, in ovarian neoplasia (2003) (96)
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (95)
Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. (2009) (93)
Biological significance of prolactin in gynecologic cancers. (2009) (93)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers (2012) (92)
Differential methylation profile of ovarian cancer in tissues and plasma. (2009) (92)
Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. (2008) (92)
Bone sialoprotein and osteopontin in bone metastasis of osteotropic cancers. (2014) (92)
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion (2014) (91)
Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. (2007) (91)
A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1. (1994) (89)
Anomalous expression of epithelial differentiation-determining GATA factors in ovarian tumorigenesis. (2003) (89)
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. (2018) (86)
Loss of A-type lamin expression compromises nuclear envelope integrity in breast cancer (2011) (86)
The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium. (2008) (86)
Exosomes as mediators of platinum resistance in ovarian cancer (2017) (85)
Identification in the Human Candidate Tumor Suppressor GeneHIC-1 of a New Major Alternative TATA-less Promoter Positively Regulated by p53* (2001) (84)
Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations (2002) (84)
Cloning and characterization of human colon glyoxalase-I. (1993) (84)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (84)
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (82)
A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. (1993) (81)
High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study (2017) (80)
Nuclear envelope structural defects cause chromosomal numerical instability and aneuploidy in ovarian cancer (2011) (79)
Pathology of Breast andOvarian Cancers among BRCA 1 and BRCA 2 Mutation Carriers : Results from the Consortium of Investigators of Modi fi ers of BRCA 1 / 2 ( CIMBA ) (2011) (78)
Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression (2006) (78)
Drug Repurposing for Gastrointestinal Stromal Tumor (2013) (77)
An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription (2011) (77)
Association Between BRCA 1 and BRCA 2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer (2012) (77)
Loss of surface and cyst epithelial basement membranes and preneoplastic morphologic changes in prophylactic oophorectomies (2003) (76)
Glutathione and drug resistance. (1996) (76)
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. (2016) (76)
BRCC36 is essential for ionizing radiation-induced BRCA1 phosphorylation and nuclear foci formation. (2006) (76)
Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. (2008) (75)
Increased Expression of the Pro-Protein Convertase Furin Predicts Decreased Survival in Ovarian Cancer (2007) (75)
Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms. (2006) (74)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
Molecular events associated with dysplastic morphologic transformation and initiation of ovarian tumorigenicity (2002) (74)
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts (2007) (73)
Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization (1997) (73)
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. (2012) (72)
Predisposition to Cancer Caused by Genetic and Functional Defects of Mammalian Atad5 (2011) (72)
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations (1999) (71)
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
Overexpression of insulin‐like growth factor 1 receptor and frequent mutational inactivation of SDHA in wild‐type SDHB‐negative gastrointestinal stromal tumors (2013) (70)
Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel (2018) (69)
Linking transcriptional elongation and messenger RNA export to metastatic breast cancers. (2005) (68)
Dynamic alterations of the extracellular environment of ovarian surface epithelial cells in premalignant transformation, tumorigenicity, and metastasis (2002) (67)
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression (2018) (67)
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients (2021) (67)
Shared heritability and functional enrichment across six solid cancers (2018) (67)
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. (2013) (65)
Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of BRCA1 or BRCA2 Mutations (2010) (65)
Loss of GATA6 Leads to Nuclear Deformation and Aneuploidy in Ovarian Cancer (2009) (64)
Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. (1999) (63)
Serum antimüllerian hormone in healthy premenopausal women. (2011) (63)
Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. (2009) (62)
Tumor-derived exosomes (2014) (61)
Loss of GATA4 and GATA6 Expression Specifies Ovarian Cancer Histological Subtypes and Precedes Neoplastic Transformation of Ovarian Surface Epithelia (2009) (60)
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2012) (60)
BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research (2009) (60)
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants (2020) (60)
Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling. (2010) (59)
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313) (2017) (58)
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor (2009) (58)
White Spot Syndrome Virus Open Reading Frame 222 Encodes a Viral E3 Ligase and Mediates Degradation of a Host Tumor Suppressor via Ubiquitination (2006) (58)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus (2016) (58)
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk. (2010) (57)
Effects of hypoxia on detoxicating enzyme activity and expression in HT29 colon adenocarcinoma cells. (1994) (57)
Robust gene expression and mutation analyses of RNA-sequencing of formalin-fixed diagnostic tumor samples (2015) (57)
Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells (2020) (56)
The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing (2011) (56)
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. (2001) (55)
Targeted or whole genome sequencing of formalin fixed tissue samples: potential applications in cancer genomics (2015) (55)
Microarrays in cancer: research and applications. (2003) (55)
Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma (2012) (55)
Identification of fifteen novel germline variants in the BRCA1 3′UTR reveals a variant in a breast cancer case that introduces a functional miR‐103 target site (2012) (55)
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (55)
Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. (2006) (54)
The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene (2003) (54)
Tumor Necrosis Factor-α-Induced Matrix Proteolytic Enzyme Production and Basement Membrane Remodeling by Human Ovarian Surface Epithelial Cells (2004) (54)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (53)
Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers (2009) (53)
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2010) (53)
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. (2012) (53)
Enhanced Counseling for Women Undergoing BRCA1/2 Testing: Impact on Subsequent Decision Making About Risk Reduction Behaviors (2005) (52)
Effective Inhibition of c-MET-mediated Signaling, Growth, and Migration of Ovarian Cancer Cells is Influenced by the Ovarian Tissue Microenvironment (2013) (52)
Ovarian normal and tumor-associated fibroblasts retain in vivo stromal characteristics in a 3-D matrix-dependent manner. (2008) (51)
Quality Assessment and Data Analysis for microRNA Expression Arrays (2008) (51)
A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. (2011) (50)
Epigenetic downregulation of the DNA repair gene MED1/MBD4 in colorectal and ovarian cancer (2009) (49)
Expression of two mucin antigens in cultured human ovarian surface epithelium: Influence of a family hostory of ovarian cancer (1995) (49)
ACRIN 6665/RTOG 0132 Phase II Trial of Neoadjuvant Imatinib Mesylate for Operable Malignant Gastrointestinal Stromal Tumor: Monitoring with 18F-FDG PET and Correlation with Genotype and GLUT4 Expression (2012) (49)
An RNA Interference Lethality Screen of the Human Druggable Genome to Identify Molecular Vulnerabilities in Epithelial Ovarian Cancer (2012) (49)
Identification and structural analysis of human RBM8A and RBM8B: two highly conserved RNA-binding motif proteins that interact with OVCA1, a candidate tumor suppressor. (2000) (48)
High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors (2009) (48)
Adenoviral transduction of TESTIN gene into breast and uterine cancer cell lines promotes apoptosis and tumor reduction in vivo. (2005) (48)
No Increased Risk of Breast Cancer Associated with Alcohol Consumption among Carriers of BRCA1 and BRCA2 Mutations Ages <50 Years (2006) (47)
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers (2012) (47)
The I1307K APC mutation does not predispose to colorectal cancer in Jewish Ashkenazi breast and breast-ovarian cancer kindreds. (1997) (46)
Decreased expression of retinol-binding proteins is associated with malignant transformation of the ovarian surface epithelium. (2002) (46)
A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. (2018) (45)
Perceived Stress is Associated with Impaired T-Cell Response to HPV16 in Women with Cervical Dysplasia (2008) (45)
MTrasT24, a metallothionein-ras fusion gene, modulates expression in cultured rat liver cells of two genes associated with in vivo liver cancer. (1988) (44)
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer (2016) (43)
Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers* (2017) (43)
Microfluidic-based solid phase extraction of cell free DNA. (2018) (43)
The prognostic value of BRCA1 promoter methylation in early stage triple negative breast cancer (2014) (43)
Novel surface targets and serum biomarkers from the ovarian cancer vasculature (2011) (42)
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. (2011) (42)
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion (2015) (42)
The APC I1307K allele and breast cancer risk (1998) (41)
Telomeric instability and reduced proliferative potential in ovarian surface epithelial cells from women with a family history of ovarian cancer. (1999) (41)
Nuclear Entry of Activated MAPK Is Restricted in Primary Ovarian and Mammary Epithelial Cells (2010) (40)
Disabled-2 Mediates c-Fos Suppression and the Cell Growth Regulatory Activity of Retinoic Acid in Embryonic Carcinoma Cells* (2001) (40)
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). (2020) (40)
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (39)
Molecular cloning and characterization of LOH11CR2A, a new gene within a refined minimal region of LOH at 11q23. (1997) (38)
Variable baseline gamma-glutamylcysteine synthetase messenger RNA expression in peripheral mononuclear cells of cancer patients, and its induction by buthionine sulfoximine treatment. (1993) (38)
Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer (2012) (38)
Proteome Changes in Ovarian Epithelial Cells Derived from Women with BRCA1 Mutations and Family Histories of Cancer * (2005) (38)
Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis (2007) (37)
AURKA F31I Polymorphism and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: A Consortium of Investigators of Modifiers of BRCA1/2 Study (2007) (37)
Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers (2015) (37)
A Multicenter Pilot Study Examining the Role of Circulating Tumor Cells as a Blood-Based Tumor Marker in Patients with Extensive Small-Cell Lung Cancer (2014) (37)
Growth regulation of ovarian cancer. (1992) (37)
Differential Expressions of Adhesive Molecules and Proteases Define Mechanisms of Ovarian Tumor Cell Matrix Penetration/Invasion (2011) (37)
The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors (2008) (37)
Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells (2014) (36)
Expression of two mucin antigens in cultured human ovarian surface epithelium: influence of a family history of ovarian cancer. (1996) (36)
Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years (2008) (36)
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6 q 14 and 20 q 11 (2012) (36)
Isolation and analysis methods of extracellular vesicles (EVs) (2020) (35)
In vivo imaging and therapeutic treatments in an orthotopic mouse model of ovarian cancer. (2010) (35)
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. (2006) (35)
A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. (2012) (35)
Drug Repurposing Identifies a Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumor (2014) (34)
Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case (2015) (34)
The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis (2011) (34)
Altered gene expression in phenotypically normal renal cells from carriers of tumor suppressor gene mutations (2004) (33)
Clinical and molecular characteristics of gastrointestinal stromal tumors in the pediatric and young adult population (2009) (33)
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. (2019) (33)
Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I–III Triple-negative Breast Cancer (NeoSTOP) (2020) (33)
DNA array‐based method for detection of large rearrangements in the BRCA1 gene (2002) (33)
Prostate cancer risk assessment program: a 10-year update of cancer detection. (2007) (33)
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416). (2020) (33)
Licofelone Enhances the Efficacy of Paclitaxel in Ovarian Cancer by Reversing Drug Resistance and Tumor Stem-like Properties. (2018) (32)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (32)
Genomic Differentiation of 18S Ribosomal DNA and β-Satellite DNA in the Hominoid and its Evolutionary Aspects (2004) (32)
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers (2010) (31)
Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers (2020) (31)
Ultrasensitive quantification of tumor mRNAs in extracellular vesicles with an integrated microfluidic digital analysis chip. (2018) (31)
Role of gamma-synuclein in microtubule regulation. (2011) (31)
In silico and in vitro drug screening identifies new therapeutic approaches for Ewing sarcoma (2016) (30)
Early and late responses to induction of rasT24 expression in Rat-1 cells. (1990) (30)
Regulation of a metallothionein-rasT24 fusion gene by zinc results in graded alterations in cell morphology and growth. (1987) (30)
Retroviral-like sequences specifically expressed in the rat ovary detect genetic differences between normal and transformed rat ovarian surface epithelial cells. (1995) (30)
Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (29)
Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor (2016) (29)
Age-dependent morphological alterations of human ovaries from populations with and without BRCA mutations. (2006) (29)
A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer (2015) (29)
The AIB1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2006) (28)
Sequencing of Candidate Chromosome Instability Genes in Endometrial Cancers Reveals Somatic Mutations in ESCO1, CHTF18, and MRE11A (2013) (28)
Expression of Siglec-11 by human and chimpanzee ovarian stromal cells, with uniquely human ligands: implications for human ovarian physiology and pathology. (2011) (28)
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers (2016) (28)
Enhanced counselling for women undergoing BRCA1/2 testing: Impact on knowledge and psychological distress–results from a randomised clinical trial (2010) (28)
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) (2009) (28)
Prospective Case–Control Study of Serum Müllerian Inhibiting Substance and Breast Cancer Risk (2009) (28)
Involvement of RHO GTPases and ERK in synuclein-γ enhanced cancer cell motility (2006) (28)
Molecular research directions in the management of gastrointestinal stromal tumors (2005) (27)
Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred (2003) (26)
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. (2013) (25)
OVCA2 is downregulated and degraded during retinoid‐induced apoptosis (2002) (25)
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers (2017) (25)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (25)
Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death (2012) (24)
Targeting progesterone signaling prevents metastatic ovarian cancer (2020) (24)
Involvement of RHO GTPases and ERK in synuclein-gamma enhanced cancer cell motility. (2006) (24)
WJMSC‐derived small extracellular vesicle enhance T cell suppression through PD‐L1 (2021) (23)
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers (2012) (23)
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial. (2019) (23)
Clinical and biomarker results from phase I/II study of PI3K inhibitor BYL 719 (alpelisib) plus nab-paclitaxel in HER2-negative metastatic breast cancer. (2018) (22)
Role of miR-139 as a surrogate marker for tumor aggression in breast cancer. (2017) (22)
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers (2012) (22)
Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer (2016) (22)
Breast cancer risk variants at 6 q 25 display different phenotype associations and regulate ESR 1 , RMND 1 and CCDC 170 (2016) (22)
The molecular pathogenesis of gastrointestinal stromal tumors. (2006) (22)
The APCI1307K allele and breast cancer risk. (1998) (22)
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells (2017) (21)
Exploring the link between MORF4L1 and risk of breast cancer (2011) (21)
Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumors and in peripheral mononuclear cells in response to mitomycin C treatment. (1996) (21)
The Role of Compounds Derived from Natural Supplement as Anticancer Agents in Renal Cell Carcinoma: A Review (2017) (21)
Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. (2016) (21)
ZNF-Mediated Resistance to Imatinib Mesylate in Gastrointestinal Stromal Tumor (2013) (21)
Identification of a second G–C-rich promoter conserved in the human, murine and rat tumor suppressor genes HIC1 (2004) (21)
Molecular mechanisms of action of imatinib mesylate in human ovarian cancer: a proteomic analysis. (2008) (20)
A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors (2012) (20)
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (20)
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
Acculturative Stress and Inflammation Among Chinese Immigrant Women (2014) (20)
Ovarian Cancer Genetics: Subtypes and Risk Factors (2018) (19)
Genome Scanning Detects Amplification of the Cathepsin B Gene (CtsB) in Transformed Rat Ovarian Surface Epithelial Cells (1999) (19)
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers (2011) (19)
Tumor necrosis factor-alpha-induced matrix proteolytic enzyme production and basement membrane remodeling by human ovarian surface epithelial cells: molecular basis linking ovulation and cancer risk. (2004) (19)
PTN signaling: Components and mechanistic insights in human ovarian cancer (2015) (19)
Loss of TNF-α-regulated COX-2 expression in ovarian cancer cells (2005) (19)
Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum (2013) (18)
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. (2016) (18)
Cloning and localization of a human diphthamide biosynthesis-like protein-2 gene, DPH2L2. (1998) (18)
Genetic Variation in IGF2 and HTRA1 and Breast Cancer Risk among BRCA1 and BRCA2 Carriers (2011) (18)
Culturally Appropriate Education Intervention on Biospecimen Research Participation among Chinese Americans (2014) (18)
Transformation of rat ovarian epithelial and Rat-1 fibroblast cell lines by RAST24 does not influence cisplatin sensitivity. (1993) (18)
Defining etiologic heterogeneity in breast cancer using genetic biomarkers. (1997) (18)
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer (2021) (17)
Molecular assessment of circulating exosomes toward liquid biopsy diagnosis of Ewing sarcoma family of tumors (2018) (17)
Differential Gene Expression Analysis by DNA Microarray Technology and Its Application in Molecular Oncology (2003) (17)
Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1 (2014) (17)
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. (2018) (17)
Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype. (1991) (17)
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (17)
Allelic imbalance in BRCA 1 and BRCA 2 gene expression is associated with an increased breast cancer risk (2008) (17)
A Phase I Study to Evaluate Two Doses of Wharton’s Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease (2020) (16)
Alteration of Differentiation Potentials by Modulating GATA Transcription Factors in Murine Embryonic Stem Cells (2010) (16)
Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer (2017) (16)
Transcriptome-wide association study of breast cancer risk by estrogen-receptor status (2020) (16)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers (2012) (16)
Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines. (1996) (15)
Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers (2020) (15)
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
Variability in loss of constitutional heterozygosity across loci and among individuals: Association with candidate genes in ductal breast carcinoma (1996) (15)
Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis (2019) (15)
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers (2019) (15)
In vitro and in vivo regulation of liver epithelial cells carrying a metallothionein‐rasT24 fusion gene (1988) (14)
Common Genetic Variants and Modification of Penetrance of BRCA 2-Associated Breast Cancer (2010) (14)
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 (2012) (14)
Downregulation of miR-506-3p Facilitates EGFR-TKI Resistance through Induction of Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines (2020) (14)
Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease (2014) (13)
Efficacy of neoadjuvant carboplatin/docetaxel chemotherapy in sporadic and BRCA-associated triple-negative breast cancer (TNBC). (2014) (13)
No evidence that GATA3 rs570613 SNP modifies breast cancer risk (2009) (13)
Novel germline BRCA1 mutation (155del4) in an African American with early‐onset breast cancer (1999) (13)
Screening, Imaging, and Early Diagnosis of Ovarian Cancer (1994) (13)
Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer (2019) (13)
Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial. (2019) (13)
Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer (1995) (12)
BRCA1-associated complexes: new targets to overcome breast cancer radiation resistance (2006) (12)
Elevation of glucose transporter, c‐myc, and transin RNA levels by Ha‐rasT24 is independent of its effect on the cell cycle (1991) (12)
NEMO, a Transcriptional Target of Estrogen and Progesterone, Is Linked to Tumor Suppressor PML in Breast Cancer. (2017) (12)
Ras/MAPK Pathway Confers Basement Membrane Dependence upon Endoderm Differentiation of Embryonic Carcinoma Cells* (2002) (12)
Mass spectrometric identification of serine hydrolase OVCA2 in the medulloblastoma cell line DAOY. (2006) (12)
Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. (2020) (12)
Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT). (2022) (12)
Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy (2019) (11)
Early ovarian cancer: a review of its genetic and biologic factors, detection, and treatment. (1996) (11)
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells. (2017) (11)
Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro (2009) (11)
An updated h-index measures both the primary and total scientific output of a researcher (2015) (11)
Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation (2020) (11)
Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry (2011) (11)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (11)
Identification of cognitive profiles among women considering BRCA1/2 testing through the utilisation of cluster analytic techniques (2011) (10)
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant (2021) (10)
Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer: Importance of Targeting c-MET and HGF Interaction. (2017) (10)
Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing. (2009) (10)
A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. (2012) (10)
Transcriptional Regulation of hTREX84 in Human Cancer Cells (2012) (10)
WNT and inflammatory signaling distinguish human Fallopian tube epithelial cell populations (2020) (10)
Ovca1, a candidate gene of the genetic modifier of Tp53, Mop2, affects mouse embryonic lethality (2008) (10)
AURKA F 31 I Polymorphism and Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers : A Consortium of Investigators of Modifiers of BRCA 1 / 2 Study (2007) (10)
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers (2012) (10)
Haploinsufficiency in tumor predisposition syndromes: altered genomic transcription in morphologically normal cells heterozygous for VHL or TSC mutation (2016) (10)
Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320). (2019) (10)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2016) (9)
Promoter Hypermethylation of the PALB 2 Susceptibility Gene in Inherited and Sporadic Breast and Ovarian Cancer (2008) (9)
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores (2021) (9)
Loss of TNF-alpha-regulated COX-2 expression in ovarian cancer cells. (2005) (9)
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer. (2021) (9)
Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes (2019) (9)
Ultrasensitive detection of circulating exosomes with a 3D-nanopatterned microfluidic chip (2019) (8)
Increased expression of the proprotein convertase furin predicts decreased survival in ovarian cancer 1 (2014) (8)
Molecular biology of gynecologic malignancies. (1998) (8)
Tumor-infiltrating nerves create an electro-physiologically active microenvironment and contribute to treatment resistance (2020) (8)
Colorectal , and Ovarian Cancer Screening Trial Specimens Ovarian Cancer Biomarker Performance in Prostate , Lung , Updated (2011) (8)
Determination of GP88 (progranulin) expression in breast tumor biopsies improves the risk predictive value of the Nottingham Prognostic Index (2016) (8)
Developing a genetic signature to predict drug response in ovarian cancer (2017) (8)
Pharmacological ascorbate induces ‘BRCAness’ and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer (2020) (8)
Exploring the link between MORF4L1 and risk of breast cancer (2011) (8)
Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant. (2022) (8)
Insulin-like growth factor 1 receptor (IGF-1R): A potential therapeutic target for gastrointestinal stromal tumors (GIST) (2008) (7)
The same γ‐glutamyl transpeptidase RNA species is expressed in fetal liver, hepatic carcinomas, and rasT24‐transformed rat liver epithelial cells (1992) (7)
Psychosocial processes in genetic risk assessment for breast cancer. (2006) (7)
Bench to Bedside and Back Again: Personalizing Treatment for Patients with GIST (2011) (7)
Modification of BRCA 1-and BRCA 2-associated Breast Cancer Risk by AIB 1 Genotype and Reproductive History 1 (2001) (7)
Anti-human embryonic stem cell monoclonal antibody Hesca-2 binds to a glycan epitope commonly found on carcinomas. (2011) (7)
Expression of OVCA 1 , a Candidate Tumor Suppressor , Is Reduced in Tumors and Inhibits Growth of Ovarian Cancer Cells 1 (1999) (7)
Genetic Variation in IGF 2 and HTRA 1 and Breast Cancer Risk among BRCA 1 and BRCA 2 Carriers (2011) (6)
Altered Gene Expression in Morphologically Normal Epithelial Cells from Heterozygous Carriers of BRCA 1 or BRCA 2 Mutations (2009) (6)
AURKA inhibition mimics BRCAness (2017) (6)
BRCA-1, BRCA-2 and Hereditary Breast Cancer (2002) (6)
Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy. (2016) (6)
Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of BRCA2 mutation carriers (2012) (6)
Analysis of Pre- and Posttreatment Tissues from the SWOG S0800 Trial Reveals an Effect of Neoadjuvant Chemotherapy on the Breast Cancer Genome (2020) (6)
Chemical carcinogens induce cadmium resistance and activate metallothionein genes in cadmium sensitive S49 mouse cells. (1985) (6)
Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC). (2021) (6)
A Single Nucleotide Polymorphism in the 5 Untranslated Region of RAD 51 and Risk of Cancer among BRCA 1 / 2 Mutation Carriers 1 (2001) (6)
Mouse‐INtraDuctal (MIND): an in vivo model for studying the underlying mechanisms of DCIS malignancy (2021) (6)
The AIB 1 Polyglutamine Repeat Does Not Modify Breast Cancer Risk in BRCA 1 and BRCA 2 Mutation Carriers (2006) (6)
BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression (2020) (5)
Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers (2010) (5)
Drug resistance in ovarian cancer and potential for its reversal (1995) (5)
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer (2022) (5)
Nano pom-poms prepared exosomes enable highly specific cancer biomarker detection (2022) (5)
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (5)
Follicle Depletion Provides a Permissive Environment for Ovarian Carcinogenesis (2016) (5)
Evaluation of nilotinib (N) in advanced GIST previously treated with imatinib mesylate (IM) and sunitinib (S). (2010) (5)
EGFR mutations in ovarian cancer correlate with response to gefitinib in a phase II trial of relapsed, persistent ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study (2005) (5)
β‐glucuronidase (2020) (4)
Erratum: A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study (Gynecol Oncol 127 (2012) (538-543)) (2013) (4)
Individualizing care for ovarian cancer patients using big data. (2014) (4)
Green Tea Cancer Prevention (2011) (4)
Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor (2015) (4)
Correction: Epimorphin-Induced MET Sensitizes Ovarian Cancer Cells to Platinum (2013) (4)
Development and Characterization of Reference Materials for MTHFR , SERPINA 1 , RET , BRCA 1 , and BRCA 2 Genetic Testing (2010) (4)
Abstract GS4-07: Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, residual cancer burden class and neo-bioscore (2021) (4)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imaging (2014) (4)
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. (2007) (4)
Nano Pom-poms Prepared Highly Specific Extracellular Vesicles Expand the Detectable Cancer Biomarkers (2021) (4)
Telomere length changes in human cancer. (2002) (3)
A window of opportunity trial of atorvastatin in p53-mutant and p53 wild type malignancies. (2019) (3)
20Telomere Length Changes in Human Cancer (2002) (3)
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial. (2023) (3)
MicroRNA Content of Ewing Sarcoma Derived Extracellular Vesicles Leads to Biomarker Potential and Identification of a Previously Undocumented EWS-FLI1 Translocation (2022) (3)
Phase II trial of single-agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash (2007) (3)
Flower lose, a cell fitness marker, predicts COVID‐19 prognosis (2021) (3)
BCL9/STAT3 regulation of transcriptional enhancer networks promote DCIS progression (2020) (3)
Impact of Germline BRCA Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer (2019) (3)
Using custom protein microarrays to identify autoantibody biomarkers for the early detection of breast cancer. (2009) (3)
Prospective longitudinal study of kinetics of humoral response to one, two, or three doses of SARS-CoV-2 vaccine in hematopoietic cell transplant recipients (2022) (3)
Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis. (2017) (3)
The same gamma-glutamyl transpeptidase RNA species is expressed in fetal liver, hepatic carcinomas, and rasT24-transformed rat liver epithelial cells. (1992) (3)
Inflammation and breast density among female Chinese immigrants: exploring variations across neighborhoods (2019) (3)
Biomarker profiling of steroid‐resistant chronic GvHD patients undergoing extracorporeal photopheresis demonstrates high ST2 levels at treatment onset and decline during therapy (2019) (3)
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor–Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial (2021) (2)
Abstract P6-11-08: Safety and efficacy results from phase I study of BYL 719 plus nab-paclitaxel in HER 2 negative metastatic breast cancer (2017) (2)
Phase II Study of Gefitinib in Patientswith Relapsed or Persistent Ovarian or Primary Peritoneal Carcinoma and Evaluation of Epidermal Growth Factor Receptor Mutations and Immunohistochemical Expression : A Gynecologic Oncology Group Study (2005) (2)
Molecular and Cellular Pathobiology Wnt 5 a Suppresses Epithelial Ovarian Cancer by Promoting Cellular Senescence (2011) (2)
Impact of DNA repair deficiency signature on outcomes in triple negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313). (2017) (2)
Analysis of ERCC1 (excision repair cross complementing group 1) in squamous cell carcinoma of the head and neck (SCCHN) by quantitative immunohistochemistry (IHC) using FL297. (2010) (2)
LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing (2019) (2)
Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer (2020) (2)
Comparison of flow cytometry and next-generation sequencing in minimal residual disease monitoring of acute myeloid leukemia: One institute's practical clinical experience. (2021) (2)
Microarrays in cancer: Research and applications: Introduction (2003) (2)
Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer. (2015) (2)
Susceptibility to Breast Cancer in CHK2 Mutation Carriers (2001) (2)
Abstract PS2-04: Evaluating serum thymidine kinase 1 in hormone receptor positive metastatic breast cancer patients receiving first line endocrine therapy in the SWOG S0226 trial (2021) (1)
Older Patients with NPM1 Mutated AML Have Distinctive Genomic Mutation Landscape Associated with Enrichment in Immunosuppressive Gene Signature (2019) (1)
Abstract 3457: Rebastinib, a TIE2 antagonist improves chemotherapy response in homologous recombination proficient epithelial ovarian cancer murine models (2022) (1)
Abstract PO-043: A prospective testing SARS-Cov-2/COVID-19 in cancer patients with antitumor treatment (2020) (1)
Comprehensive analysis of cancer stemness (2018) (1)
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers (2022) (1)
Correlation of gastrointestinal stromal tumor (GIST) gene expression signatures and response to imatinib mesylate in the Radiation Therapy Oncology Group phase II clinical trial S-0132. (2016) (1)
Clinical and Molecular Characteristics of Gastrointestinal Stromal Tumor in the Pediatric and Young Adult Population (2010) (1)
Breast Cancer Risk and 6 q 22 . 33 : Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA 1 / 2 (2012) (1)
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers (2012) (1)
Impact of Protein InteractionTechnologies on Cancer Biology and Pharmacogenetics (2005) (1)
A Phase I Trial of Irinotecan (IRI) and BKM120 in Previously Treated Patients (PTS) With Metastic Colorectal Cancer (MCRC) (2012) (1)
Genomes & Developmental Control Perception of differentiation cues by GATA factors in primitive endoderm lineage determination of mouse embryonic stem cells (2005) (1)
Syddansk Universitet Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12 p 11 locus (2016) (1)
Abstract PD9-06: Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial (2022) (1)
Gastrointestinal tumors, colorectal (2012) (1)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (1)
Irinotecan (Iri) and buparlisib (B) in previously treated patients (pts) with metastatic colorectal cancer (mCRC). (2015) (1)
P-134 Expression of constitutively activated EGFRvIII in non-small cell lung cancer (2003) (1)
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women (2016) (1)
The Activation Marker CD137 (4-1BB) Identifies a Highly Active Subset of Donor Lymphocytes Against Acute Myeloid Leukemia (2019) (1)
Effect of Erbitux on cell viability is correlated with the responsive signaling pathway(s) but not EGFR expression levels in ovarian tumor cells (2005) (1)
Chapter 3 – Enzymatic and Chemical Cleavage Methods to Identify Genetic Variation (2010) (1)
phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers (2015) (1)
Editorial Expression of Concern: Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25–q27 (2017) (1)
Abstract P3-06-16: Thrombocytopenia is associated with pathological complete response to neoadjuvant carboplatin/docetaxel chemotherapy inBRCAwild type triple negative breast cancer (2015) (1)
Polygenic Risk Modelling for Prediction of Epithelial Ovarian Cancer Risk (2020) (1)
Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers (2015) (1)
The Role of Information Systems in Clinical and Translational Research (Frontiers: The NIH Clinical and Translational Science Award Driving Information Systems) (2012) (1)
Abstract B29: Outcomes of DNA repair-deficient pancreatic cancers: KU Cancer Center experience (2019) (1)
Microfluidic affinity selection of active SARS-CoV-2 virus particles (2022) (1)
Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1 (2014) (1)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers (2016) (1)
Prospective evaluation of BRCA mutations in a large triple-negative breast cancer (TNBC) registry: Implications for germline testing. (2013) (1)
Facilitating preventive behaviors among women undergoing BRCA1/2 Testing (2004) (1)
Abstract 4553: Gedunin, a novel HSP-90 inhibitor, synergizes with cisplatin and paclitaxel to inhibit growth of chemoresistant ovarian cancer cell lines (2014) (1)
Abstract P4-08-06: Impact of molecular subtypes on long-term outcomes in triple-negative breast cancer (TNBC) patients treated with adjuvant AC chemotherapy on SWOG S9313 (2019) (1)
Identiﬁcation of four novel susceptibility loci for oestrogen receptor negative breast cancer (2016) (1)
Erratum: Isolation and analysis methods of extracellular vesicles (EVs) (2021) (1)
Exploration of biomarkers from a pilot weight management study for men undergoing radical prostatectomy. (2021) (1)
Abstract 3501: Entinostat enhances the efficacy of olaparib in preclinical models of ovarian cancer (2019) (1)
Abstract 2752: Genetic heterogeneity of ovarian cancer survival effects inBRCA1/2germline mutations: a large, multi-center study (2011) (1)
Gastrointestinal Stromal Tumors: From Molecular Pathogenesis to Therapy (2013) (1)
Tumor-Derived Extracellular Vesicles as Complementary Prognostic Factors to Circulating Tumor Cells in Metastatic Breast Cancer (2023) (1)
Abstract 1776: Impact of homologous recombination deficiency (HRD) biomarkers on outcomes in triple-negative breast cancer (TNBC) patients treated with AC chemotherapy (SWOG S9313) (2017) (1)
Abstract P2-05-05: Expression profiling of in vivo DCIS progression models identified BCL9 as a molecular driver of invasive progression (2016) (1)
CRISPR/Cas9-Mediated Disruption of PD-L1 Reduces the T Cell Suppressive Effect of Wharton's Jelly Mesenchymal Stromal Cells and Their Extracellular Vesicles (2018) (1)
Abstract B03: Targeting the KIF11/KIF15/TPX2 axis to develop new therapies for ovarian cancer (2018) (1)
Anomalous expression of GATA factors underlies the loss of Disabled-2 expression and ovarian tumorigenesis (2004) (0)
Abstract P2-08-16: Impact of germlineBRCAmutation status on survival in women with metastatic triple negative breast cancer (2019) (0)
q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers (2012) (0)
Expression in HT 29 Colon Adenocarcinoma Cells Effects of Hypoxia on Detoxicating Enzyme Activity and Updated (2006) (0)
Association of GP88 (progranulin) tumor expression with decreased disease-free and overall survivals in patients with breast cancer with estrogen receptor-positive invasive ductal carcinoma. (2011) (0)
Construction and Analysis of the NCI-EDRN Breast Cancer Reference Set for Circulating Markers of Disease Running Title : Breast Cancer Reference Set for Circulating Markers (2014) (0)
Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226) (2023) (0)
Mechanisms Tumors : AKT Signaling Dependent and Independent Therapeutic Effect of Imatinib in Gastrointestinal Stromal (2006) (0)
Abstract 276: Targeting signaling networks via RNAi to improve therapy for ovarian cancer (2012) (0)
Abstract 2804: ERCC1 (excision repair cross complementing group 1) is a predictive biomarker of survival in squamous cell carcinoma of the head and neck (SCCHN) (2010) (0)
Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/HSP90 signaling axis (2019) (0)
Title Interplay between BRCA 1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer (2012) (0)
Abstract 433: Expression of stem cell and EMT markers on circulating tumor cells (2012) (0)
Abstract 777: Down-regulation of miR-506 contributes to EGFR-TKI resistance through inducing sonic hedgehog signaling in non-small cell lung cancer (2019) (0)
Abstract A126: Analysis of excision repair cross complementing group 1 (ERCC1) expression in squamous cell carcinoma of the head and neck (SCCHN) (2009) (0)
Gamma Synuclein Promotes a Metastatic Phenotype in Breast and Ovarian Tumor Cells by Modulating the Rho Signal Transduction Activity (2002) (0)
Gleevec and gastrointestinal stromal tumors Identification of response markers and the molecular mechanisms of action (2003) (0)
Compositions et procedes destines au traitement du cancer, au criblage des composants anticancereux presumes et a l'estimation de l'evolution du cancer (2003) (0)
Abstract PD5-09: Mouse-intraductal (MIND): The first in vivo model to recapitulate the full spectrum of human DCIS pathology (2021) (0)
Abstract A06: Integration of synthetic lethality and genomic data to identify significant molecular vulnerabilities in ovarian cancer (2013) (0)
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer (2019) (0)
Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer (2016) (0)
Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease (2022) (0)
High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study (2017) (0)
Progranulin (GP88) tumor tissue expression is associated with increased risk of recurrence in breast cancer patients diagnosed with estrogen receptor positive invasive ductal carcinoma (2012) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Cell Cycle , Cell Death , and Senescence Enhancer of Zeste Homolog 2 Promotes the Proliferation and Invasion of Epithelial Ovarian Cancer Cells (2010) (0)
Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia‐related changes: A single institution experience (2022) (0)
Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
A framework for personalized mammogram screening (2021) (0)
Abstract P5-16-02: Pathological complete response is associated with excellent outcomes inBRCAmutation associated triple negative breast cancer (2017) (0)
Abstract P4-10-06: Influence of older age on triple negative breast cancer (TNBC) clinical-pathological characteristics and outcomes (2018) (0)
P3.03-13 Downregulation of miRNA-506 Mediates EGFR-TKI Resistance Through Inducing Sonic Hedgehog Signaling in Non-Small-Cell Lung Cancer Cell Lines (2018) (0)
Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation (2020) (0)
A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors (2023) (0)
Abstract PR04: Progress towards development of an exosome-based biomarker assay in Ewing sarcoma (2018) (0)
Prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800) using image analysis-based tumor infiltrating lymphocyte measurements. (2022) (0)
Abstract 4969: RNA interference screens to identify genes essential for ovarian tumor growth and maintenance (2011) (0)
University of Groningen Design, optimization, and multisite evaluation of a targeted next-generation sequencing assay system for RNA fusions and exon-skipping events in non-small cell lung cancer. Blidner, (2019) (0)
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. (2023) (0)
Abstract 1565: Targeting of KIF11 and AURKA to improve outcomes in Ewing sarcoma (2023) (0)
Molecular Biomarkers of Columnar Cell Lesions Identified by Proteomic Approaches. (2009) (0)
Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy (2023) (0)
Shared heritability and functional enrichment across six solid cancers (2019) (0)
Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials (2023) (0)
Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results (2023) (0)
Quality Assessment and Data Analysis for microRNA Expression Arrays Supplementary Material (2008) (0)
Abstract 1764: Accurate and reproducible detection of fusions and exon skipping events in NSCLC-derived samples using a comprehensive, targeted RNA-Seq system across multiple laboratories (2017) (0)
Abstract B01: B cell lymphoma 9 mediates a cross talk between the canonical Wnt and EGFR signaling in breast cancer (2016) (0)
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer (2022) (0)
Proteomic Profiling of Fallopian Tube-Derived Extracellular Vesicles Using a Microfluidic Tissue-on-Chip System (2023) (0)
Abstract P1-03-06: Improvement in risk predictive value of Nottingham prognostic index by determining GP88 tumor tissue expression for estrogen receptor positive breast cancer patients (2017) (0)
ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease (2023) (0)
Abstract P4-12-03: Triple-negative breast cancer: Frequency of inherited mutations in breast cancer susceptibility genes (2015) (0)
Microfluidic Multistage Integration for Analysis of Circulating Exosomes (2016) (0)
University of Groningen DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Osorio, (2014) (0)
ociation of the Variants CASP 8 D 302 H and CASP 10 0 I with Breast and Ovarian Cancer Risk in B & P A 1 and BRCA 2 Mutation Carriers (2010) (0)
Abstract GS3-05: Classification of triple negative breast cancer (TNBC) by DNA damage immune response (DDIR) signature and homologous recombination deficiency (HRD) status: Analysis of SWOG S9313 adjuvant trial (2021) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Association of Aurora kinase A and epidermal growth factor receptor (EGFR) gene copy number with overall survival in KRAS wild-type patients with metastatic colorectal cancer. (2010) (0)
Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses (2020) (0)
Polygenic risk modeling for prediction of epithelial ovarian cancer risk (2022) (0)
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | NOVA. The University of Newcastle's Digital Repository (2014) (0)
Abstract 1230: Wnt5a-dependent induction of senescence suppresses epithelial ovarian cancer (2011) (0)
Characterization of an In Vitro model of MGUS Progression to Multiple Myeloma (2016) (0)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (0)
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial (2023) (0)
Developing Inhibitors of Ovarian Cancer Progression by Targeted Disruption of the Gamma-Synuclein Activated Migratory and Survival Signaling Pathways (2007) (0)
Case report: Invasive fungal infection in a patient with a rare CVID-causing gene (TNFRSF13B) mutation undergoing AML treatment (2023) (0)
Cancer esearch cular and Cellular Pathobiology RAS-Variant in Ovarian Cancer Acts as a Genetic R ker of Cancer (2010) (0)
Abstract P6-14-08: Epithelial/stromal cross talks that induce malignant transition of human ductal carcinoma in situ (2023) (0)
Abstract P2-11-11: Computer analysis of nuclear morphology with Multiple Instance Learning Predicts Overall Survival for Node Positive Breast Cancer Patients from SWOG S8814: A Blinded Validation Study (2023) (0)
Effects of Hypoxiaon DetoxicatingEnzymeActivity and Expressionin HT29 Colon Adenocarcinoma Cells (1994) (0)
Abstract PS6-04: Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2 negative breast cancer (2021) (0)
Advancing the promises of precision medicine for patients with gastrointestinal stromal tumor (2019) (0)
Abstract 3927: Evaluating new therapies in Gastrointestinal Stromal Tumor using in vivo molecular optical imaging. (2013) (0)
Abstract PD8-08: Development of humanized immune DCIS models using patient peripheral blood derived hematopoietic stem cells (CD34+) (2019) (0)
Electronic Supplemental Information Microfluidic-based Solid Phase Extraction of Cell Free DNA (2018) (0)
Abstract POSTER-THER-1409: Targeting p53-FoxM1 axis in ovarian cancer (2015) (0)
Abstract POSTER-TECH-1109: Robust gene expression and mutation analyses from RNA-sequencing of formalin-fixed diagnostic tumor samples (2015) (0)
Abstract 4141: EWS-FLI regulates mitotic kinesins in Ewing sarcoma family of tumors (2018) (0)
536PA PHASE I TRIAL OF IRINOTECAN (IRI) AND BUPARLISIB IN PREVIOUSLY TREATED PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC): FINAL RESULTS. (2014) (0)
Cancer esearch cular and Cellular Pathobiology egulation of DLX 5 Promotes Ovarian Cancer Cell R liferation by Enhancing IRS-2-AKT Signaling (2010) (0)
A Phase IIa, Double-Blinded, Randomized Placebo-Controlled Trial of MAPKAPK2 Inhibition by ATI-450 in Treatment of Moderate-Severe COVID-19 Pneumonia (2021) (0)
Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression (2018) (0)
Integrated genomic characterization of oesophageal carcinoma (2017) (0)
Abstract 1627: Fibroblast HGF elicits c-MET-mediated signaling and migration in ovarian cancer cells. (2013) (0)
TITLE: Identification of Pro-differentiation p53 Target Genes and E valuation of Expression in Normal and Malignant Mammary Gland (2006) (0)
The putative tumor suppressor WWOX protein is normally expressed in surface ovarian epithelium and frequently lost in ovarian carcinomas (2004) (0)
Molecular and Cellular Pathobiology 19 p 13 . 1 Is a Triple-Negative – Speci fi c Breast Cancer Susceptibility Locus (2012) (0)
The prognosis of NF1 mutations in newly diagnosed AML: A single-center retrospective study. (2019) (0)
Abstract P5-14-06: Lapatinib reverses endocrine resistance in select patients with HER2 negative, hormone positive metastatic breast cancer (2016) (0)
Inter- and intra-individual variability in somatic allele loss in ductal carcinoma of the breast (1994) (0)
Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus (2016) (0)
Overall survival based on MSI and BRAF mutation status for stage II/III colorectal cancer. (2021) (0)
Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion (2015) (0)
BRCC36, A Novel Subunit of a BRCA1/2 E3 Ubiquitin Ligase Complex: Candidate Breast Cancer Susceptibility Gene (2004) (0)
Male breast cancer in BRCA1 and BRCA2 mutation carriers (2018) (0)
Ovarian Surface Epithelium The Differential Role of L 1 in Ovarian Carcinoma and Normal (2008) (0)
Identification of small extracellular vesicle protein biomarkers for pediatric Ewing Sarcoma (2023) (0)
Identification of Candidate Breast Cancer Susceptibility Genes Using a cDNA Microarray/CGH Approach (2002) (0)
Optimizing Retrieval of Biospecimens Using the Curated Cancer Clinical Outcomes Database (C3OD) (2019) (0)
prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer (2012) (0)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (0)
Abstract 5334: Targeting the KIF15-TPX2 PPI to overcome KIF11 inhibitor resistance in epithelial ovarian cancer (2023) (0)
A window of opportunity trial of atorvastatin targeting p53 mutant malignancies (2019) (0)
Human Peripheral Blood Mononucleocyte Derived Myeloid Committed Progenitor Cells Mitigate H-ARS by Exosomal Paracrine Signal (2022) (0)
ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate (IM) for primary and recurrent operable malignant GIST: Imaging findings and correlation with genotype and GLUT4 expression. (2016) (0)
Abstract 310: The role of c-Jun N-terminal kinase 2alpha in non-small cell lung carcinoma tumorigenesis (2010) (0)
SNP rs2180341 per-allele hazard ratios (HRs) and 95% confidence intervals (CIs) among Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) in A. BRCA1 mutation carriers B. BRCA2 mutation carriers. (2012) (0)
egulation of DLX5 Promotes Ovarian Cancer Cell (2010) (0)
Communicating risk and the landscape of cancer prevention — an exploratory study that examines perceptions of cancer-related genetic counseling and testing among African Americans and Latinos in the Midwest (2023) (0)
Facilitating preventive behaviors among women undergoing BRCA1/2 Testing. (2004) (0)
WNT and inflammatory signaling distinguish human Fallopian tube epithelial cell populations (2020) (0)
LAG3 Promotes Acute Myeloid Leukemia-Induced Immune Suppression (2018) (0)
A Therapeutic Trial Validating the Physiologically Based Pharmacokinetic Simulation of the Dose-Exposure Relationship of Metformin in Young Children with Insulin Resistance or Type 2 Diabetes Mellitus (2021) (0)
Abstract P2-11-16: Computerized Measurements of Nuclear Morphology Features, Mitosis Rate, and Tubule Formation from H&E Images Predicts Disease-Free Survival in Patients with HR+ & LN+ Invasive Breast Cancer from SWOG S8814 (2023) (0)
Abstract 5306: IRAK1: A novel TOLLway to target ovarian cancer (2022) (0)
Chemical carcinogens induce cadmium resistance and activate quiescent metallothionein genes (1985) (0)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
Abstract ED06-02: Circulating ovarian cancer biomarkers and early detection (2013) (0)
Cell Reports Resource The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (0)
Effect of hierarchical clustered sampling in multicenter, family-based studies: Example of reproductive history and breast cancer risk in BRCA1 mutation carriers. (2000) (0)
Abstract 1379: Entinostat induces PARPi sensitivity across multiple ovarian cancer models (2020) (0)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (0)
The Nuclear Death Domain Protein p84N5; a Candidate Breast Cancer Susceptibility Gene (2005) (0)
Abstract P4-10-03: Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer (2022) (0)
An in vitro Model for Evaluating Autologous T-cell and Tumor Cell Interactions in Renal Cell Carcinoma (2021) (0)
Nano Pom-Poms Prepared Exosomes for Highly Specific Cancer Biomarker Detection (2021) (0)
Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer (2014) (0)
Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case (2015) (0)
University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch, (2013) (0)
Abstract LB-373: Comprehensive analysis of cancer stemness (2018) (0)
Exosomes, PD-L1 and aGvHD: Perspectives for WJMSCmediated Therapy (2021) (0)
Abstract 4281: Targeted or whole genome sequencing of formalin-fixed tissue samples (2014) (0)
Abstract P4-06-01: Patient derived DCIS mouse-intraductal (MIND) models recapitulate the full spectrum of human patient pathology and histologic features including progression to invasion in a subset of cases (2017) (0)
Circulating tumor cells (CTC) as a biomarker of response in patients with extensive-stage small cell lung cancer (EX-SCLC). (2013) (0)
Overcoming Wnt–β-catenin dependent anticancer therapy resistance in leukaemia stem cells (2020) (0)
ALK alteration association with prognosis in metastatic colorectal cancer: A single institution retrospective cohort study. (2018) (0)
Gene expression signatures associated with resistance to imatinib mesylate (2010) (0)
Author Correction: A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (0)
Promoter hypermethylation leading to inactivation of MED1 DNA repair gene is present in human colorectal and ovarian cancer (2006) (0)
Prognosis of NF1 Mutations in Acute Myeloid Leukemia (2022) (0)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (0)
Abstract 3351: Identification of novel biomarkers for high grade serous ovarian cancer screening via extracellular vesicle proteomic profiling (2023) (0)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
Abstract B20: In silico and in vitro drug screening identifies new therapeutic approaches targeting DNA double-strand breaks repair in Ewing sarcoma (2016) (0)
Vitamin D insufficiency as a peripheral neuropathy risk factor in white and black patients in SWOG 0221. (2022) (0)
Growth Guidance Cue (2011) (0)
Correction: Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers (2018) (0)
Abstract 485: Modulation of microRNA expression in EGFR-tyrosine kinase inhibitor-resistant non-small cell lung cancer cell lines (2018) (0)
Abstract 3301: Ultrasensitive compartment-free digital phenotyping of circulating extracellular vesicles for diagnosis of Ewing sarcoma (2023) (0)
Abstract 2008: Genomic medicine using NexGen sequencing to personalized treatment of metastatic adenoid cystic carcinoma (ADCC). (2013) (0)
Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE Study (2021) (0)
Abstract P13: Prospective voluntary SARS-CoV-2 virus and anti-COVID-19 antibody tests in asymptomatic medical and research staff who work in direct contact with cancer patients: A single center study (2021) (0)
Assessing Breast Cancer Molecular Subtypes Using Extracellular Vesicles' mRNA. (2023) (0)
Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers (2017) (0)
Exosomes for the Early Detection of Ovarian Cancer (2016) (0)
P2-12-32: Association between Progranulin (GP88) Expression and Recurrence Risk for Breast Cancer Patients with Estrogen Receptor Positive Invasive Ductal Carcinoma. (2011) (0)
Abstract PD13-02: Site of recurrence after neoadjuvant therapy: A multi-center pooled analysis (2021) (0)
Abstract 1570: Early Detection Research Network (EDRN) validation of circulating ovarian cancer biomarkers (2015) (0)
Use of non-anthracycline adjuvant chemotherapy in triple-negative breast cancer: Review from a prospective registry. (2015) (0)
AKT2, a putative oncogene encoding a member of a novel subfamily of serine-threonine protein kinases, is amplified and overexpressed in human ovarian carcinomas (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Andrew K Godwin?

Andrew K Godwin is affiliated with the following schools:

Andrew K Godwin's Academic­Influence.com Rankings

Andrew K Godwin's Degrees

Similar Degrees You Can Earn

Why Is Andrew K Godwin Influential?

Andrew K Godwin's Published Works

Published Works

What Schools Are Affiliated With Andrew K Godwin?

Andrew K Godwin's AcademicInfluence.com Rankings